Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
Presentation With Live Webcast on October 21, 2015 at 11:30 a.m. PDT / 2:30 p.m. EDT
(firmenpresse) - NORWOOD, MA -- (Marketwired) -- 10/13/15 -- (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the Company's Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting at the 14th Annual on Wednesday, October 21, 2015 at 11:30 a.m. Pacific Time at the Parc 55 in San Francisco, California.
Dr. Cohen will provide an update on the Company's clinical development program for its investigational drug, , a novel synthetic oral drug with the potential to treat chronic inflammation and fibrosis in rare diseases. Resunab is currently being studied in three separate Phase 2 clinical trials for the treatment of , diffuse cutaneous and .
A live audio webcast will be available by accessing the in the section of the Corbus website (). The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.
is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The 14th Annual is an international biotech investor conference focused on early and established private companies as well as emerging public companies. BIO also produces the , the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Resunab™ is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in pre-clinical models of inflammation and fibrosis. Resunab triggers the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of pro-inflammatory eicosanoids and cytokines. Resunab has direct effects on fibroblasts to halt tissue scarring. In effect, Resunab triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunab™, is a novel synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation, bacterial infections, and fibrotic processes. Resunab is currently in Phase 2 studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis and skin-predominant dermatomyositis.
For more information, please visit and connect with the Company on , , and .
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email:
David Schull or Marissa Goberdhan
Russo Partners, LLC
Phone: +1 (858) 717-2310
Email:
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.10.2015 - 11:00 Uhr
Sprache: Deutsch
News-ID 426354
Anzahl Zeichen: 0
contact information:
Town:
NORWOOD, MA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 259 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum"
steht unter der journalistisch-redaktionellen Verantwortung von
Corbus Pharmaceuticals Holdings Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
